药物类型 单克隆抗体 |
别名 SHR 1209、SHR-1209 |
靶点 |
作用机制 PCSK9抑制剂(前蛋白转化酶枯草杆菌蛋白酶Kexin-9抑制剂) |
在研适应症 |
原研机构 |
非在研机构- |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
高胆固醇血症 | 申请上市 | 中国 | 2023-06-21 | |
高胆固醇血症 | 申请上市 | 中国 | 2023-06-21 | |
家族性混合型高脂血症 | 临床3期 | 中国 | 2021-07-30 | |
合并高脂血症 | 临床3期 | 中国 | 2021-04-23 | |
II型高脂蛋白血症 | 临床3期 | 中国 | 2021-04-23 | |
III型高脂蛋白血症 | 临床3期 | 中国 | 2021-04-23 | |
V型高脂蛋白血症 | 临床3期 | 中国 | 2021-04-23 | |
常染色体显性遗传性高胆固醇血症3型 | 临床3期 | 中国 | 2021-04-14 | |
原发性高胆固醇血症 | 临床3期 | 中国 | 2021-04-14 | |
纯合子家族性高胆固醇血症 | 临床2期 | - | 2020-09-01 |
临床3期 | 703 | recaticimab at 150 mg every 4 weeks | 糧憲襯製鹹積鹹顧憲願(憲顧艱蓋積願淵糧願範) = Safety with recaticimab was comparable to placebo. the most common treatment-related adverse event was injection site reaction (n = 23 [4.9%]). 蓋齋網膚範齋艱齋衊鑰 (簾築觸積鑰餘憲鏇獵齋 ) | 积极 | 2024-10-23 | ||
recaticimab at 300 mg every 8 weeks | |||||||
临床3期 | 689 | recaticimab 150 mg (injection every 4 weeks) | 廠憲醖選醖餘願積觸膚(艱鬱糧夢艱夢鬱鏇艱鏇) = At every dosage/interval, participants who received recaticimab had lower bad cholesterol levels at 24 weeks than those receiving a placebo.
In the 4-week injection group, bad cholesterol was reduced 62% among those taking recaticimab vs. 0% among those in the placebo group; in the 8-week injection group, bad cholesterol was reduced 59% vs. +0.4% respectively; and in the 12-week injection group bad cholesterol was reduced 51% vs. +2% respectively.
At every dosage/interval, recaticimab lowered their bad cholesterol to the target by 24 weeks compared to the placebo and these levels were maintained at 48 weeks. 願願衊艱願壓窪顧憲蓋 (膚膚糧鹽積選襯糧糧淵 ) 更多 | 积极 | 2023-11-13 | ||
Placebo (injection every 4 weeks) | |||||||
临床1/2期 | 110 | 窪構築遞壓遞淵壓獵顧(窪淵遞鬱膚餘鑰積觸鏇) = No serious treatment-emergent adverse events (TEAEs) occurred. 廠構夢齋鏇窪糧鑰簾願 (淵齋蓋鑰糧艱鹽餘鹽壓 ) 更多 | 积极 | 2022-01-18 | |||
Placebo |